View Gilead Sciences, Inc. (GILD) current and estimated P/E ratio data provided by Seeking Alpha.

Gilead Sciences rose 2% in early trading, after the biotech reported positive data for a long-acting HIV prevention drug that promises to be a big seller. The drug, called lenacapavir, was 96% ...

Co-founder Finny Kuruvilla manages the firm’s largest two funds — Eventide Gilead and Eventide Healthcare and Life Sciences — and remains the firm’s largest owner, though more than 20 of ...

Gilead Sciences Inc.’s twice-yearly HIV prevention shot prevented almost all HIV cases in a large trial in men and transgender people, a result that will allow the company to file for approval ...

While some investors are already well versed in financial metrics (hat tip), this article is for those who would ...

Gilead's news was that its second phase 3 trial of HIV drug lenacapavir met its key efficacy endpoints for preventing the disease. An interim analysis of the study found that the drug reduced new ...

Drugmaker Gilead has announced that its new, twice-a-year shot of lenacapavir reduced HIV infections by 96% in a Phase 3 clinical trial. The company will next seek approval from the U.S. Food ...

Chris Schott has given his Buy rating due to a combination of factors revolving around Gilead Sciences’ drug, lenacapavir, and its potential impact on the market. Schott points out the ...

Your donation makes it possible for us to keep doing this important work, keeping you informed every step of the way to the November election Drugmaker Gilead Science announced Thursday that its ...

Gilead Sciences’ Kite Pharma will sell its stake in China’s Fosun Kite Biotechnology nearly eight years after forming the 50-50 cell-therapy-focused joint venture with Fosun Pharma. Fosun ...

**NM signifies a non meaningful value. A dash signifies the data is not available.

Baylen, Paige Cowett, Rowan Niemisto, Dan Powell, Elisheba Ittoop, Marion Lozano and Alyssa Moxley Gilead delayed a new version of a drug, allowing it to extend the patent life of a ...